Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
November 9, 2007
By: Tim Wright
Editor-in-Chief, Contract Pharma
PharmEng International has opened its $15 million pharmaceutical manufacturing facility in Cape Breton, Nova Scotia, Canada. The 46,400-sq.ft. facility, which operates under the name of Keata Pharma, includes offices for PharmEng’s pharmaceutical consulting division, pilot laboratories for formulation development, rooms with various capabilities such as high shear mixing, container blending and equipment for modified release technology in a control environment that meets all cGMP requirements. The facility will have the necessary equipment and approvals to provide formulation development and testing services to manufacture and package products in solid and liquid dosage forms. Keata’s long-term goal is to develop capabilities in other dosage forms, such as suppositories, topicals and injectables, according to a PharmEng statement. The facility is located on five acres in the Northside Industrial Park, a 300-acre business park in North Sydney, NS. “We are committed to delivering the best value to all of our customers and are proud of the role Keata and its employees will play in the Cape Breton community,” said Alan Kwong, President of PharmEng “Cape Breton’s readily available infrastructure, skilled workforce and government support, coupled with PharmEng’s technology leadership and expertise, gives us the confidence in delivering the best value in manufacturing services to our customers.” The facility will initially employ 65 workers and is anticipated to grow to more than 150 workers within three years. It is the only plant of its kind in Nova Scotia and one of the few plants in Canada that offers modified release manufacturing capabilities, according to the company. Production is expected to commence in early Q1 of 2008. The Government of Canada has invested $6.25 million in repayable contributions for the construction of the facility through the Cape Breton Growth Fund ($5 million), Enterprise Cape Breton Corporation ($750,000), and ACOA’s Business Development Program ($500,000).
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !